Sharing experiences about preclinical models and probiotics!
Did you know that ETAP-Lab has been working in the field of probiotics for more than 15 years, being pioneer in the preclinical study of the gut-brain axis? ETAP-Lab will share its experiences about probiotics testing in preclinical models during the 19th Meet&Match event focused on microbiome, a virtual event scheduled the 1st of July. Dr Jean-François Bisson will talk about: “Assessing beneficial effects of probiotics in small animal models: ETAP-Lab ‘s experience” during Session II at 11h55. This event is co-organized by BioValley France
Bio Digital: Meet us at the World’s Largest Virtual Partnering Experience!
ETAP-Lab will be attending BIODigital as part of the BusinessFrance virtual French pavilion (from 10 to 18 June). Our experts Dr. Jean-François Bisson (VP) and Dr. Nicolas Violle (CEO) will be there to introduce you to the laboratory's activities in preclinical Dermatology, NutritionHealth and Neurology, with Stroke, Alzheimer’s and Parkinson’s diseases. Please feel free to contact us to schedule a video conference. We’re hoping to meet you soon!
Alzheimer’s Disease – a new preclinical model #2
Intracerebral administration of AB1-42 (AβO) oligomers disrupts synaptic function and increases cell death in brain tissue in aged mice. As announced a few weeks ago, we evaluated the effects of AβO on synaptic function and cell survival. Quantification of protein expression in the hippocampus 18 days after intracerebral administration showed disruption to synaptic function (PSD-95) and apoptotic signalling in brain tissue. Figure 1: Graphical representation of PSD-95 expression and Bax/Bcl-2 ratio in the hippocampus, 18 days after AβO
Alzheimer’s Disease – a new preclinical model
As announced a few weeks ago, we tested the effects of donepezil (DPZ) in our Alzheimer's disease model, induced by the administration of beta-amyloid oligomers 1-42. We have shown that memory disorders induced by A-Beta oligomers could be significantly reduced by this symptomatic treatment of Alzheimer's disease. This strengthens the pharmacological validity of our model. In addition, we have once again shown the reproducibility of our model. We have shown that the deleterious effects on memory induced by the administration of A-beta
New model for Alzheimer’s Disease – First batch of data!
The toxicity of our beta-amyloid peptide oligomers is confirmed in vivo in elderly mice After several months’ development, several replicated studies show that oligomers of A-beta peptides (whose neurotoxicity in vitro is well documented), induce cognitive deficits in object recognition test and Morris watermaze in the weeks following intracerebroventricular injection in 18-month-old mice. We have shown that the administration of A-beta 1-42 oligomers leads to significant memory impairment in the object recognition test: while animals in the vehicle group show a significant
Merry Christmas and a Happy New Year 2021
All of us here at ETAP-Lab and STROK@LLIANCE hope all of you are in good health, and wish you every success in all your endeavours, in 2021 and beyond. As we approach the end of this year unlike any other, we wanted to let you know how ETAP-Lab has managed - and share our plans for 2021 with you. During the health crisis Despite two periods of lockdown ETAP-Lab’s activity has not diminished - quite the opposite, in fact! Having ground to an
Approval for the first psychobiotics: ETAP-Lab is proud to have played a role
In partnership with Lallemand Health Solutions, Aspen Farmacêutica is bringing the first psychobiotic formulation for the gut-brain axis to the Brazilian market. The two finished products are Probid and Probians and contain two strains of probiotics for which the following claims are now approved: Lactobacillus helveticus Rosell-52 and Bifidobacterium longum Rosell-175 may contribute to the reduction of feelings of anxiety in healthy individuals. Lactobacillus helveticus Rosell-52 and Bifidobacterium longum Rosell-175 contribute to the reduction of gastrointestinal complications (such as abdominal pain and nausea/vomiting) brought on by light
EWMA: Presentation of the results of work we conducted for URGO laboratories
Preclinical research carried out in a rat skin healing model that has shown the efficacy of a sucrose octasulfate dressing (UrgoStart) will be presented at the EWMA Digital Congress - 18 and 19 November 2020. We were able to show that the accelerated healing achieved by use of the innovative UrgoStart dressings was linked to faster and denser reconstruction of the local vascular network, in comparison with control conditions in rats. These results, invaluable for URGO laboratories, have made it possible
Our tau oligomer toxicity – a new tool for drug screening
The toxicity of the tau oligomers produced by ETAP-Lab can be reversed by using BDNF on primary rat neuron cultures. BNDF applied at the same time as tau oligomers significantly and reproducibly reduced cell mortality. Incubation of cortical neurons with Tau monomers, TauO and TauO+BDNF. TauO decreased quite significantly cell viability (*; p<0.01), while monomers showed no neurotoxic effect. Incubation with BDNF significantly reversed TauO-induced neurotoxicity (#; p<0.01). Data are expressed as percent of vehicle (set at 100%) and represent the mean ± SD. (N=3, n=12). This tauopathy model is now
ETAP-Lab a is expanding and recruiting a new employee for STROK@LLIANCE
ETAP-Lab a is expanding and recruiting a new employee for STROK@LLIANCE: there is a new Laboratory technician – Research assistant position available at STROK@LLIANCE(Caen, FRANCE). Please find here the If you fit to this profile, please contact us at recruitment@etap-lab.com Un nouveau poste de technicien de laboratoire – assistant de recherche est ouvert chez STROK@ALLIANCE (Caen, FRANCE). La description du poste est disponible